New drug shown to improve bone growth in children with achondroplasia
A phase 3 global clinical trial showed a new drug boosts bone growth in children born with achondroplasia by blocking the activity of FGFR3 protein, potentially returning growth rates to normal. The experimental drug vosoritide was safe and effective in increasing bone growth over one year.